supported by the National Key Research and Development Program of China(2022YFC2604100,2022YFC2302900,2021YFC2301400,and 2022YFE0131700);National Natural Science Foundation of China(92169208,32222031,82071813,32141004,and 82171775);Peking University People’s Hospital Research and Development Funds(RDGS2022-05);National Postdoctoral Program for Innovative Talents of China(BX20220332)。
Studies have focused on neutralizing antibody titers and T-cell activation induced by vaccination against different SARS-CoV-2strains[1,2].Advanced single-cell technology has allowed for a comprehensive evaluation of ...
Supported by National Key Research and Development Program of China,No.2021YFC2701900 and No.2016YFC1305300.
BACKGROUND The coronavirus disease 2019(COVID-19)pandemic has been linked to an increased incidence of diabetes and diabetic ketoacidosis(DKA).However,the relationship between COVID-19 infection and progression to typ...
supported by Guangzhou Laboratory,Grant Award Number:EKPG21-30-4.
The safety and efficacy of COVID-19 vaccines in the elderly,a high-risk group for severe COVID-19 infection,have not been fully understood.To clarify these issues,this prospective study followed up 157 elderly and 73 ...
Background We explored the influence of diabetes on the antibody levels of elderly individuals after inoculation with an inactivated vaccine against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and the f...
supported by the National Science and Technology Major Project of China(Nos 2017ZX10202203-007,2017ZX10202203-008,2018ZX10302206-003)and a pilot project of clinical cooperation between traditional Chinese and western medicine for significant and complicated diseases of National Administration of Traditional Chinese Medicine:hepatic fibrosis.We also acknowledge the support of the National Natural Science Foundation of China(No 81772198);Natural Science Foundation of Chongqing,China(No.cstc2020jcyjmsxmX0389).
Background and Aims:SARS-CoV-2 vaccines-associated autoimmune liver diseases have been reported in several case reports.However,the safety and immunogenicity after primary and booster inactivated SARS-CoV-2 vaccinatio...
Key Research and Development Project of the Science and Technology Department of Sichuan Province(No.2021YFS0003,Zygd18020);High-level Talents Fund of the Wuhu Municipal Government(No.2021-134)
To the Editor:The latest variant of concern,Omicron,has become the dominant global variant immediately after it was first reported in November 2021.[1]It contains>30 mutations in the spike protein,with 17 mutations in...
Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has been spreading globally since its initial outbreak in 2019.Substantial evidence has revealed that children who are receiving antitumor therapy or hematopo...
supported by the Emergency Key Program of Guangzhou Laboratory(No.EKPG21-30);the Fundamental Research Funds for the Central Universities(No.2019kfyXMBZ015);the Fellowship of China Postdoctoral Science Foundation(Nos.2020T130034ZX and 2020M680102);the National Natural Science Foundation of China(Nos.72061137006 and 82204113).
Emerging SARS-CoV-2 variants have made COVID-19 convalescents susceptible to re-infection and have raised concern about the efficacy of inactivated vaccination in neutralization against emerging variants and antigen-s...
supported by the National Science and Technology Major Project of China(2017ZX10202203-007,2017 ZX10202203-008,2018ZX10302206-003);Remarkable Innovation-Clinical Research Project,The Second Affiliated Hospital of Chongqing Medical University and The First batch of key Disciplines On Public Health in Chongqing;support of the National Natural Science Foundation of China(81772198);Natural Science Foundation of Chongqing,China(cstc2020jcyj-msxmX0389).
Background and Aims:Our aim was to determine the immune efficacy of a severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)booster vaccination in cirrhotic patients who had received the primary series.Methods:We...
This work was supported by funds from the National Key R&D Program of China(2021YFA1301400 to B.S.,Y.X.,L.-S.Y.,and 2021YFC2301500 to Y.W.);the National Natural Science Foundation of China(31722020 to L.-S.Y.,31930035,91942311 and 32061143028 to B.S.);Shanghai Science and Technology Commission(20410714000,20JC410100 and 22JC1402600 to B.S.).
Dear Editor,Since the emergence of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)in 2019,the virus has continued to evolve resulting in new waves of infection and immune escape in the vaccinated populatio...